Loading…
Reported covered position: None.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · fourth_quarter · Q4
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Source: Senate LDA
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Inflation Reduction Act of 2022
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · third_quarter · Q3
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Issues related to Pharmacy Benefit Manager reform (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness; HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · second_quarter · Q2
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of2022 Title I, Subtitle B, Parts 1-3.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2023 · second_quarter · RA
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · fourth_quarter · Q4
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · third_quarter · Q3
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills); HR 5376 Build Back Better Act/Inflation Reduction Act of 2022 Title I, Subtitle B, Parts 1-3.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). FDA User Fee Reauthorization Act of 2022.
Issues related to Bayh-Dole Act (Pub.L. 96-517).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · second_quarter · Q2
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2022 · first_quarter · Q1
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · fourth_quarter · Q4
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · third_quarter · Q3
Issues related to Bayh-Dole Act (Pub.L. 96-517).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · second_quarter · Q2
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2021 · first_quarter · Q1
Issues related to Medicare Part D policies, including patient access, non-interference and rebate policy issues. Drug costs and pricing issues. Transparency policy issues. H.R.3 Lower Drug Costs Now Act of 2019, H.R.19 Lower Costs, More Cures Act of 2019, S.2543 Prescription Drug Pricing Reduction Act, and S.3129 Lower Costs, More Cures. General issue on the need for the Centers for Medicare & Medicaid Services to increase awareness around the need for screening and treatment for various cancers during the Covid-19 pandemic (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2008 · first_quarter · RA
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy, (no specific bills). Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to Bayh-Dole Act (Pub. L. 96-517).